Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mithramycin in Thoracic Malignancies
NCT01624090Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2012
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Mithramycin in lung carcinoma, esophageal carcinoma, Thymic neoplasm, germ cell tumor (GCT), malignant pleural mesothelioma (MPM), sponsored by National Cancer Institute. Started Sep 2012; status: terminated.
02
Drugs
Mithramycin
03
Conditions
lung carcinomaesophageal carcinomaThymic neoplasmgerm cell tumor (GCT)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01624090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624090.